Beam Therapeutics Inc. (BEAM)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $2.58B
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Latest financial period: June 30, 2026
Filed with the SEC: August 4, 2026
Estimated earnings date: November 3, 2026
Profit #1317 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 8.8% | 9.6% | 8.7% | 5.5% |
Growth #349 of 1484 companies
Payout #1117 of 1484 companies
Safety #835 of 1484 companies
Price #1430 of 1484 companies
